Table 1.

Characteristics of patients

ID	Age at start of therapy (y)	Age at evaluation (y)	Sex	Therapy	Duration of therapy (y)	ECV*	Diastolic classification
CCH01	2.3	11	Male	Chronic transfusions, hydroxyurea	8.9	0.29	No diastolic dysfunction
CCH02	2.7	17	Female	Chronic transfusions	14.6	0.27	No diastolic dysfunction
CCH03	1.7	8	Male	Chronic transfusions, hydroxyurea	6.6	0.26	Inconclusive
CCH04	1.9	7	Female	Chronic transfusions, hydroxyurea	5.9	0.29	No diastolic dysfunction
CCH05	1.1	7	Male	Chronic transfusions	6.5	0.34	No diastolic dysfunction
CHL01	3	28	Female	Chronic transfusions	24.9	0.37	No diastolic dysfunction
CHL02	3.4	24	Female	Hydroxyurea	20.9	0.28	No diastolic dysfunction
CHL03	3.2	19	Female	Chronic transfusions	15.8	0.28	No diastolic dysfunction
CHL04	4.5	22	Female	Hydroxyurea	17.4	0.28	No diastolic dysfunction
CHL05	5.4	21	Female	Chronic transfusions	11.7	0.36	Inconclusive
CHL06	5.5	23	Female	Hydroxyurea	17	0.33	No diastolic dysfunction
CHL07	2.4	16	Male	Hydroxyurea	13.7	0.29	No diastolic dysfunction

^*ECV for normal controls: 0.26 ± 0.02; ECV for patients with untreated SCA: 0.44 ± 0.08.